[1] 焦洋, 宁洁, 王芳, 等.替吉奥联合顺铂与替吉奥联合奥沙利铂一线治疗晚期胃癌的比较研究[J].临床肿瘤学杂志, 2012, 17(3):246.
[2] MOEHLER M, LYROS O, GOCKEL I, et al.Multidisciplinary management of gastric and gastroesophageal cancers[J]. World J Gastroenterol, 2008, 14(24):3773. doi: 10.3748/wjg.14.3773
[3] SMALLEY SR, BENEDETTI JK, HALLER DG, et al.Updated analysis of SWOG-directed intergroup study 0116:a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J]. J Clin Oncol, 2012, 30(19):2327. doi: 10.1200/JCO.2011.36.7136
[4] PARK SH, SOHN TS, LEE J, et al.Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer:final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33(28):3130. doi: 10.1200/JCO.2014.58.3930
[5] NOH SH, PARK SR, YANG HK, et al.Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):5-year follow-up of an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(12):1389. doi: 10.1016/S1470-2045(14)70473-5
[6] STUMPF PK, AMINI A, JONES BL, et al.Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma:a National Cancer Data Base analysis[J]. Cancer, 2017, 123(17):3402. doi: 10.1002/cncr.30748
[7] YU JI, LIM DH, LEE J, et al.Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer[J]. Radiother Oncol, 2018, 129(2):306. doi: 10.1016/j.radonc.2018.07.002
[8] YU C, YU R, ZHU W, et al.Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery[J]. J Cancer Res Clin 0ncol, 2012, 138(2):255. doi: 10.1007/s00432-011-1085-y
[9] BAMIAS A, KARINA M, PAPAKOSTAS P, et al.A randomized phase Ⅲ study of adjuvant pIatinum/docetaxeI chemotherapy with or without radiation therapy in patients with gastric cancer[J]. Cancer Chemother Pharmacol, 2010, 65(6):1009. doi: 10.1007/s00280-010-1256-6
[10] 徐祯祯, 权循凤, 蒋俊, 等.调强放疗联合p53基因治疗中晚期宫颈癌的临床疗效[J].安徽医学, 2015, 36(1):19.
[11] WU DM, WANG S, WEN X, et al.Survival benefit of three different therapies in postoperative patients with advanced gastric cancer:A Network Meta-Analysis Front Pharmacol[J]. Front Pharmacol, 2018, 9:929. doi: 10.3389/fphar.2018.00929
[12] JABO B, SELLECK MJ, MORGAN JW, et al.Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs.chemoradiation) in patients with resected gastric cancer[J]. J Gastrointest Oncol, 2018, 9(4):708. doi: 10.21037/jgo.2018.05.12
[13] ZHOU ML, LI GC, YANG W, et al.Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer:a retrospective cohort study[J]. Br J Radiol, 2018, 91(1089):20180276.
[14] 张先稳, 李军, 张西志, 等.宫颈癌术后5野调强放疗4个变量组合的最佳治疗模式的剂量学[J].中国医学物理学杂志, 2016, 33(9):872.
[15] 杨健, 许新明, 刘颖, 等.Ⅰb和Ⅱ期宫颈癌术后调强放疗的疗效[J].武警医学, 2015, 26(10):1001.
[16] HIRAMOTO S, KIKUCHI A, TETSUSO H, et al.Efficacy of palliative radiotherapy and chemo-radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction[J]. Int J Clin Oncol, 2018, 23(6):1090. doi: 10.1007/s10147-018-1317-0
[17] 康梅, 权循凤, 李兵兵, 等.宫颈癌容积调强与固定野动态调强放疗技术的剂量学比较[J].安徽医学, 2016, 37(4):398.
[18] 李霞, 王雪桃, 李涛, 等.胃癌放射治疗中静态调强计划射野和子野的优化研究[J].华西医学, 2018, 33(4):403.
[19] 朱均强.不同子野数对中晚期宫颈癌静态调强影响的研究[J].中国医疗设备, 2016, 31(8):101.